[Bronchial superinfection. Clinical trial of clavulanic acid-amoxicillin against josamycin].
Authors report a prospective clinical an bacteriological study in 32 patients, almost with a chronic bronchopulmonary disease. A group of 16 patients was treated with the association clavulanic acid-amoxicillin (ACA) and the 16 others with josamycin (J) for an acute exacerbation of bronchitis. Pus and numeration of bacteria in expectorations were the criteria of efficacity. Better results of ACA group were assessed with 14 cures (87%) against 4 (25%) (p less than 0.001) and no failure against 4 in J group (p less than 0.05). They conclude therapy with ACA is more effective and recommended in serious acute exacerbations in chronic bronchopulmonary diseases.
Gaillat
J
J
Jacquet
J F
JF
Janin
A
A
Micoud
M
M
D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D001991:Bronchitis / Q000188:drug therapy*; D002969:Clavulanic Acids / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D006801:Humans; D007933:Leucomycins / Q000627:therapeutic use*; D011446:Prospective Studies
D002969:Clavulanic Acids; D007933:Leucomycins; D000658:Amoxicillin
Surinfection bronchique. Essai clinique acide clavulanique-amoxiciline versus josamycine.